



## Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2025

Date: 25<sup>th</sup> July 2025

**The President  
Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001**

**The Vice President,  
Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051**

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

**SUB: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Ma'am,

We have received attached intimation under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 from M/s. **HCP INVESTMENTS**, regarding acquisition of 44,85,124 equity shares upon conversion of equivalent numbers of warrants into equity on 25<sup>th</sup> July 2025.

We request you to treat this intimation as compliance with the aforesaid regulations and take the same on record.

For **IND-SWIFT LABORATORIES LTD.**



**PARDEEP VERMA  
VP-CORPORATE AFFAIRS &  
COMPANY SECRETARY**

Encl: a/a

## HCP INVESTMENTS

Unit 13, Socota Phoenicia, Sayed Hossen Road, Phoenix, Mauritius

Ref: HCP/IND/001

Date: 25<sup>th</sup> July 2025

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

**National Stock Exchange of India Limited,**  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051

**Subject: Intimation of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011**

Respected Sir/Ma'am,

Please find enclosed herewith disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 w.r.t. to acquisition of 44,85,124 equity shares of Ind Swift Laboratories Limited ("Target Company") representing 6.20% of the total paid-up share capital of the target company, upon conversion of equivalent no. of warrants into equity.

With this conversion, our total holding in the company has increased from 4.49% to 10.36%.

You are requested to kindly take the same on record.

**Thanking You**  
**For HCP Investments**



.....  
**Mr. Antonino Sardegno**  
**Director**

CC:  
Company Secretary & Compliance Officer  
Ind Swift Laboratories Limited  
SCO 850, Shivalik Enclave, NAC,  
Manimajra, Chandigarh  
160101

**Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part-A - Details of the Acquisition**

Name of the Target Company (TC)	Ind-Swift Laboratories Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	HCP Investments		
Whether the acquirer belongs to Promoter / Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited & National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			#
a) Shares carrying voting rights	30,14,876	4.49%	8.81%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	44,85,124	-	-
e) Total (a+b+c+d)	75,00,000	4.49%	8.81%
<b>Details of acquisition</b>			#
a) Shares carrying voting rights acquired	44,85,124	6.20%	8.81%
b) VRs acquired otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-

d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+/-d)	44,85,124	6.20%	8.81%
<b>After the acquisition, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	75,00,000	10.36%	8.81% <sup>#</sup>
b) VRs otherwise than by equity shares	-	-	-
c) Warrants/convertible securities /any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+d)	75,00,000	10.36%	8.81%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)	Preferential Allotment upon conversion of warrants into equity		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Acquisition of equity shares upon conversion of warrants into equity		
Date of allotment of equity shares	21-07-2025		
Date of intimation of allotment of equity shares	23-07-2025		
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 67,20,17,360/- comprising of 6,72,01,736 equity shares of face value of Rs. 10/- each immediately before allotment on 21-07-2025		
Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 72,38,68,600/- comprising of 7,23,86,860 equity shares of face value of Rs. 10/- each.		
Total diluted share/voting capital of the TC after the said acquisition	Rs. 85,08,68,600/- comprising of 8,50,86,860 equity shares of face value of Rs. 10/- each.		

# Assuming full conversion of total outstanding warrants.